1y return+141.4%S&P 500 +20.9%
3y return+175.5%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2021: $355 against $157 in the S&P 500.2
Kynam Capital Management, LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| CLDXCelldex Therapeutics Inc New | $198.1M | 10.9% | −8.9% |
| SNDXSyndax Pharmaceuticals Inc | $176.0M | 9.7% | |
| PCVXVaxcyte Inc | $169.9M | 9.4% | |
| COGTCogent Biosciences Inc | $141.9M | 7.8% | −9.2% |
| VERAVera Therapeutics Inc | $124.0M | 6.9% | −15.0% |
| VRDNViridian Therapeutics Inc | $118.6M | 6.6% | +175.6% |
| TVTXTravere Therapeutics Inc | $113.6M | 6.3% | +27.5% |
| BEAMBeam Therapeutics Inc | $97.5M | 5.4% | −22.9% |
| Urogen Pharma LtdCUSIP M96088105 | $89.6M | 5.0% | +8.3% |
| LEGNLegend Biotech Corp | $86.7M | 4.8% | +90.4% |
| CTMXCytomx Therapeutics Inc. | $81.4M | 4.5% | +44.6% |
| RLAYRelay Therapeutics Inc | $61.7M | 3.4% | +131.7% |
| CGEMCullinan Therapeutics Inc | $56.7M | 3.1% | |
| MBXMbx Biosciences Inc | $51.6M | 2.9% | |
| IMCRImmunocore Hldgs PLC | $43.7M | 2.4% | +55.4% |
| NRIXNurix Therapeutics Inc | $29.0M | 1.6% | |
| STROSutro Biopharma Inc | $29.0M | 1.6% | |
| BCRXBiocryst Pharmaceuticals Inc | $25.2M | 1.4% | −55.6% |
| Pharvaris N VCUSIP N69605108 | $22.9M | 1.3% | +3.3% |
| SMMTSummit Therapeutics Inc | $17.5M | 1.0% | New |
| PRLDPrelude Therapeutics Inc | $12.9M | 0.7% | +51.6% |
| INSMInsmed Inc | $10.7M | 0.6% | New |
| BNRBurning Rock Biotech Ltd | $10.5M | 0.6% | |
| GERNGeron Corp | $8.8M | 0.5% | |
| AMRNAmarin Corp PLC | $8.5M | 0.5% | +12.8% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| RLAYRelay Therapeutics Inc | December 31, 2024 | +354.1% | $61.7M |
| COGTCogent Biosciences Inc | June 30, 2022 | +329.0% | $141.9M |
| MBXMbx Biosciences Inc | September 30, 2025 | +215.4% | $51.6M |
| STROSutro Biopharma Inc | December 31, 2025 | +186.9% | $29.0M |
| PCVXVaxcyte Inc | December 31, 2021 | +144.3% | $169.9M |
| CADLCandel Therapeutics Inc | March 31, 2026 | +110.2% | $996K |
| Urogen Pharma LtdCUSIP M96088105 | March 31, 2026 | +104.7% | $89.6M |
| NRIXNurix Therapeutics Inc | March 31, 2025 | +104.2% | $29.0M |
| PRLDPrelude Therapeutics Inc | December 31, 2025 | +83.8% | $12.9M |
| TVTXTravere Therapeutics Inc | December 31, 2021 | +83.0% | $113.6M |
Sold off last quarter
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $36.7M
- Apellis Pharmaceuticals IncCUSIP 03753U106 was $33.2M
- Soleno Therapeutics IncCUSIP 834203309 was $18.7M
- EVMNEvommune Inc was $14.4M
- Engene Holdings IncCUSIP 29286M105 was $9.2M
- DSGNDesign Therapeutics Inc was $8.3M
- Wave Life Sciences LtdCUSIP Y95308105 was $7.0M
- CLYMClimb Bio Inc was $6.9M
- Biohaven LtdCUSIP G1110E107 was $5.9M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +15.1% | +14.8% |
| March 31, 2026 | +6.8% | −4.6% |
| December 31, 2025 | +45.5% | +2.4% |
| September 30, 2025 | +35.0% | +7.8% |
| June 30, 2025 | +0.3% | +10.5% |
| March 31, 2025 | −19.5% | −4.6% |
| December 31, 2024 | −5.4% | +2.1% |
| September 30, 2024 | +15.4% | +5.4% |
| June 30, 2024 | −1.5% | +4.0% |
| March 31, 2024 | +28.9% | +10.0% |
| December 31, 2023 | +25.0% | +11.2% |
| September 30, 2023 | −18.4% | −3.6% |
| June 30, 2023 | +1.1% | +8.3% |
| March 31, 2023 | −1.7% | +7.0% |
| December 31, 2022 | +13.1% | +7.1% |
| September 30, 2022 | +37.3% | −5.3% |
| June 30, 2022 | −9.8% | −16.5% |
| March 31, 2022 | −7.5% | −4.9% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Kynam Capital Management, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1907884&type=13F-HR&dateb=&owner=include&count=40CIK 1907884
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1907884/000190788426000012/Filed August 14, 2026 · accession 0001907884-26-000012